PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24389416-13	2014	Further prospective studies are needed to clarify whether the change in FGF-23 and sclerostin levels is a marker or a potential mechanism of the action of BPs at a vascular level.	Diphosphonates	155-158	sclerostin	Homo sapiens	83-93	
25003812-2	2014	We compared the effects of two bisphosphonate treatments on two Wnt-inhibitors Sclerostin (SOST) and Dickkopf-related protein 1 (DKK1).	Diphosphonates	31-45	sclerostin	Homo sapiens	79-89	
25003812-2	2014	We compared the effects of two bisphosphonate treatments on two Wnt-inhibitors Sclerostin (SOST) and Dickkopf-related protein 1 (DKK1).	Diphosphonates	31-45	sclerostin	Homo sapiens	91-95	
23748710-7	2013	SOST expression is increased with advancing age, by glucocorticoid treatment and during treatment with antiresorptive agents such as bisphosphonates and denosumab, while it is decreased by parathyroid hormone excess or administration of estrogens.	Diphosphonates	133-148	sclerostin	Homo sapiens	0-4	
22178539-0	2012	Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin.	Diphosphonates	0-14	sclerostin	Homo sapiens	110-120	
22178539-10	2012	In conclusions, decreased bone formation after several months of bisphosphonate therapy is associated with increased serum levels of sclerostin.	Diphosphonates	65-79	sclerostin	Homo sapiens	133-143